Literature DB >> 22722998

Allele and genotype frequencies of the polymorphic cytochrome P450 genes (CYP1A1, CYP3A4, CYP3A5, CYP2C9 and CYP2C19) in the Jordanian population.

Al-Motassem Yousef1, Nailya R Bulatova, William Newman, Nancy Hakooz, Said Ismail, Hisham Qusa, Farah Zahran, Nidaa Anwar Ababneh, Farah Hasan, Imad Zaloom, Ghada Khayat, Rawan Al-Zmili, Randa Naffa, Ola Al-Diab.   

Abstract

Drug metabolizing enzymes participate in the neutralizing of xenobiotics and biotransformation of drugs. Human cytochrome P450, particularly CYP1A1, CYP2C9, CYP2C19, CYP3A4 and CYP3A5, play an important role in drug metabolism. The genes encoding the CYP enzymes are polymorphic, and extensive data have shown that certain alleles confer reduced enzymatic function. The goal of this study was to determine the frequencies of important allelic variants of CYP1A1, CYP2C9, CYP2C19, CYP3A4 and CYP3A5 in the Jordanian population and compare them with the frequency in other ethnic groups. Genotyping of CYP1A1(m1 and m2), CYP2C9 (2 and 3), CYP2C19 (2 and 3), CYP3A4 5, CYP3A5 (3 and 6), was carried out on Jordanian subjects. Different variants allele were determined using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). CYP1A1 allele frequencies in 290 subjects were 0.764 for CYP1A1 1, 0.165 for CYP1A1 2A and 0.071 for CYP1A1 2C. CYP2C9 allele frequencies in 263 subjects were 0.797 for CYP2C9 1, 0.135 for CYP2C9 2 and 0.068 for CYP2C9 3. For CYP2C19, the frequencies of the wild type (CYP2C19 1) and the nonfunctional (2 and 3) alleles were 0.877, 0.123 and 0, respectively. Five subjects (3.16 %) were homozygous for 2/2. Regarding CYP3A4 1B, only 12 subjects out of 173 subjects (6.9 %) were heterozygote with none were mutant for this polymorphism. With respect to CYP3A5, 229 were analyzed, frequencies of CYP3A5 1, 3 and 6 were 0.071, 0.925 and 0.0022, respectively. Comparing our data with that obtained in several Caucasian, African-American and Asian populations, Jordanians are most similar to Caucasians with regard to allelic frequencies of the tested variants of CYP1A1, CYP2C9, CYP2C19, CYP3A4 and CYP3A5.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22722998     DOI: 10.1007/s11033-012-1807-5

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  83 in total

1.  CYP3A5*3 and *6 single nucleotide polymorphisms in three distinct Asian populations.

Authors:  C Balram; Qingyu Zhou; Yin Bun Cheung; Edmund J D Lee
Journal:  Eur J Clin Pharmacol       Date:  2003-05-17       Impact factor: 2.953

2.  Lung cancer risk in relation to genetic polymorphisms of microsomal epoxide hydrolase among African-Americans and Caucasians in Los Angeles County.

Authors:  S J London; J Smart; A K Daly
Journal:  Lung Cancer       Date:  2000-05       Impact factor: 5.705

3.  Allele and genotype frequencies of CYP2B6 and CYP3A5 in the Japanese population.

Authors:  Masahiro Hiratsuka; Yoh Takekuma; Naomi Endo; Kaori Narahara; Samar Ismail Hamdy; Yukinaga Kishikawa; Masaki Matsuura; Yasuyuki Agatsuma; Tomoko Inoue; Michinao Mizugaki
Journal:  Eur J Clin Pharmacol       Date:  2002-08-14       Impact factor: 2.953

4.  Genetic susceptibility to squamous cell carcinoma of the lung in relation to cigarette smoking dose.

Authors:  K Nakachi; K Imai; S Hayashi; J Watanabe; K Kawajiri
Journal:  Cancer Res       Date:  1991-10-01       Impact factor: 12.701

5.  Phenotype-genotype variability in the human CYP3A locus as assessed by the probe drug quinine and analyses of variant CYP3A4 alleles.

Authors:  Cristina Rodríguez-Antona; Jane G Sayi; Lars L Gustafsson; Leif Bertilsson; Magnus Ingelman-Sundberg
Journal:  Biochem Biophys Res Commun       Date:  2005-09-13       Impact factor: 3.575

6.  The genetic determinants of the CYP3A5 polymorphism.

Authors:  E Hustert; M Haberl; O Burk; R Wolbold; Y Q He; K Klein; A C Nuessler; P Neuhaus; J Klattig; R Eiselt; I Koch; A Zibat; J Brockmöller; J R Halpert; U M Zanger; L Wojnowski
Journal:  Pharmacogenetics       Date:  2001-12

7.  Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population.

Authors:  M G Scordo; E Aklillu; U Yasar; M L Dahl; E Spina; M Ingelman-Sundberg
Journal:  Br J Clin Pharmacol       Date:  2001-10       Impact factor: 4.335

8.  Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients.

Authors:  Eric Thervet; Dany Anglicheau; Barry King; Marie-Hélène Schlageter; Bruno Cassinat; Philippe Beaune; Christophe Legendre; Ann K Daly
Journal:  Transplantation       Date:  2003-10-27       Impact factor: 4.939

9.  CYP2C19 genotypes in a population of healthy volunteers and in children with hematological malignancies in Gaza Strip.

Authors:  Abu-Eid I Sameer; Gharbieh M Amany; Abed A Abdela; Sharif A Fadel
Journal:  Can J Clin Pharmacol       Date:  2009-02-04

10.  CYP3A4 and CYP3A5 genotyping by Pyrosequencing.

Authors:  Adam A Garsa; Howard L McLeod; Sharon Marsh
Journal:  BMC Med Genet       Date:  2005-05-09       Impact factor: 2.103

View more
  20 in total

Review 1.  Interethnic variation of CYP2C19 alleles, 'predicted' phenotypes and 'measured' metabolic phenotypes across world populations.

Authors:  I Fricke-Galindo; C Céspedes-Garro; F Rodrigues-Soares; M E G Naranjo; Á Delgado; F de Andrés; M López-López; E Peñas-Lledó; A LLerena
Journal:  Pharmacogenomics J       Date:  2015-10-27       Impact factor: 3.550

2.  Characterization of drug-metabolizing enzymes CYP2C9, CYP2C19 polymorphisms in Tunisian, Kuwaiti and Bahraini populations.

Authors:  Rania Abdelhedi; Nouha Abdelmoula Bouayed; Suad Alfadhli; Leila Abid; Ahmed Rebai; Najla Kharrat
Journal:  J Genet       Date:  2015-12       Impact factor: 1.166

3.  The cytochrome P450 2D6*10 genetic polymorphism alters postoperative analgesia.

Authors:  Xiao-Bin Wei; Xi Xiao; Zhou-Xin Han; Dan-Qin Lin; Ping Yu
Journal:  Int J Clin Exp Med       Date:  2015-02-15

4.  Factors affecting warfarin dose requirements and quality of anticoagulation in adult Egyptian patients: role of gene polymorphism.

Authors:  N S Bazan; N A Sabry; A Rizk; S Mokhtar; O A Badary
Journal:  Ir J Med Sci       Date:  2013-06-27       Impact factor: 1.568

5.  Increased bioavailability of phenylephrine by co-administration of acetaminophen: results of four open-label, crossover pharmacokinetic trials in healthy volunteers.

Authors:  Hartley C Atkinson; Ioana Stanescu; Isam I Salem; Amanda L Potts; Brian J Anderson
Journal:  Eur J Clin Pharmacol       Date:  2014-12-06       Impact factor: 2.953

6.  Genetic variation of pharmacogenomic VIP variants in the Chinese Li population: an updated research.

Authors:  Shuangyu Yang; Xia Dou; Zhen Wang; Wenjie Zhang; Kefan Ding; Wenting Meng; Haiyue Li; Jianfeng Liu; Yuanwei Liu; Tianbo Jin
Journal:  Mol Genet Genomics       Date:  2022-02-11       Impact factor: 3.291

7.  Polymorphisms and phenotypic analysis of cytochrome P450 3A4 in the Uygur population in northwest China.

Authors:  Tianbo Jin; Hua Yang; Jiayi Zhang; Zulfiya Yunus; Qiang Sun; Tingting Geng; Chao Chen; Jie Yang
Journal:  Int J Clin Exp Pathol       Date:  2015-06-01

8.  Cytochrome P450 2C9 (CYP2C9) polymorphisms in Chinese Li population.

Authors:  Yipeng Ding; Danlei Yang; Long Zhou; Ping He; Jinjian Yao; Pingdong Xie; Daobo Lin; Dingwei Sun; Pei Sun; Quanni Li; Tingting Geng; Tianbo Jin
Journal:  Int J Clin Exp Med       Date:  2015-11-15

Review 9.  Pharmacogenetics of tamoxifen therapy in Asian populations: from genetic polymorphism to clinical outcomes.

Authors:  Tingyu Wang; Yitian Zhou; Guosheng Cao
Journal:  Eur J Clin Pharmacol       Date:  2021-01-29       Impact factor: 2.953

10.  Genotype and Allele Frequency of CYP3A4 -392A>G in Turkish Patients with Major Depressive Disorder.

Authors:  Zuhal Uçkun; Bora Baskak; Hatice Özdemir; Erguvan Tuğba Özel-Kizil; Halise Devrimci-Özgüven; Halit Sinan Süzen
Journal:  Turk J Pharm Sci       Date:  2018-07-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.